SMS Campaign to Increase COVID-19 Vaccine Take-up in Tanzania

How to cite

Manda, Constantine; Fille, Christina; Ringo, Noela; Rashidi, Saidi. 2022. "SMS Campaign to Increase COVID-19 Vaccine Take-up in Tanzania." AEA RCT Registry. AEARCTR-0009832. https://doi.org/10.1257/rct.9832-2.1

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Constantine Manda* , Christina Fille , Noela Ringo , Saidi Rashidi

* Primary investigator

Registry ID
AEARCTR-0009832
DOI
https://doi.org/10.1257/rct.9832-2.1
First registered
Last updated
Status
On going
Trial dates
2022-11-24 – 2023-09-30
Countries
Private
Registry record
http://www.socialscienceregistry.org/trials/9832

Abstract

What messaging will convince Tanzanians to get a COVID-19 vaccine? We propose to use a randomized placebo-controlled trial, to evaluate an SMS campaign targeting Tanzanian mobile phone subscribers with two different SMS content aimed at increasing vaccine take up. We hypothesize different mechanisms by which Tanzanians may be induced to agree to get a COVID-19 vaccine including (1) altruism for others (empathy); and (2) COVID-19’s long term health impacts (Self interest). A placebo group of mobile subscribers will receive an SMS unrelated to the aforementioned interventions. We intend to share the effective messages, in addition to information on where to access vaccinations, with everyone in our sample no more than 3 months after treatment. Our proposed work is expected to inform literature on the social science of persuasion more broadly but specifically as it relates to persuading adults to take up health interventions, in particular, a COVID-19 vaccine. We expect our results to be highly informative not only for Tanzanian public health policy but also more broadly by providing precise estimates of precise content that may help increase COVID-19 vaccine take up and accelerate an end to this pandemic.

Intervention

We propose sending SMS messages of varying content in a randomized placebo-controlled experiment. Our experiment will be based on two (2) treatment arms which will receive two (2) different text message content and one placebo group which will receive SMS content on some other non-public health issue unrelated to COVID-19.

Treatment 1 (T1): We call this treatment the EMPATHY treatment, where mobile phone subscribers in this arm will receive an SMS message emphasizing one’s increased potential contribution to harming others through exposing them to COVID-19, in the absence of vaccination.

Treatment 2 (T2): We call this treatment the SELF - INTEREST treatment, where mobile phone subscribers in this arm will receive an SMS message on adverse long-term effects of COVID-19 infection.

Placebo group (C), where mobile phone subscribers in this arm will receive an SMS message on some other non-public health issue unrelated to COVID-19.

Experimental design

We propose to use a randomized placebo-controlled experiment. There will be two treatments (T2 and T2) and placebo group. Randomization will ensure the balance of observable and non-observable characteristics between control and experiment groups and therefore any difference between them in our outcomes of interest will be due to our proposed intervention.

Design details

Randomization method
Randomization will be done in office by a computer
Randomization unit
Mobile phone subscribers
Observations
Our targeted sample is 12,000 mobile phone subscribers. We plan to send the intervention to 17,209 nationally representative sample. If we do not reach this target, we will supplement our sample with an additional booster sample of 8,564 respondents. However, the booster sample may not be as representative of the national population as our initial sample of 17,209 nationally representative respondents.
Arms
Our analysis unit is individual phone subscribers from the IPSOS database, with a target sample size of 12,000 for our study which is distributed as 4,500; 4,500; and 3,000 for T1; T2; and Placebo, respectively. To achieve this sample size, we plan to recruit 17,209 respondents, who will be nationally representative and distributed in the same ratio as our target sample. Specifically, we aim to recruit 6,454, 6,453, and 4,302 respondents for T1, T2, and Placebo, respectively. If we did not reach the targeted sample, we will supplement our sample with additional booster sample of 8565 respondents. This will be distributed in the same ratio as above across our treatments arms.
Primary outcomes
a. Self-reported vaccination status. This will be assessed by a follow up survey question “Have you received the full dose of any COVID-19 vaccine?” b. Household members’ vaccination status. This will be assessed by a follow up survey question “How many of your household members have received the full dose of any COVID-19 vaccine?” c. Objectively verified vaccination status: “Please provide either your NIDA (national ID), passport number, voter ID, or other ID number or your full name that you used when you registered and received the COVID-19 vaccine.” d. Self-reported intent to vaccinate. This will be assessed by a follow up survey question “Do you intend, in the next 12 months, to receive the full dose of any COVID-19 vaccine?” e. Household members’ intent to vaccinate. This will be assessed by a follow up survey question “How many of your household members have expressed intentions, in the next 12 months, to receive the full dose of any COVID-19 vaccine?” f. Subjective trust on COVID-19 vaccines: From a scale of 1 to 10 where 10 is complete trust and 1 is no trust, how much do you trust the COVID-19 vaccines? g. Self-reported compliance on wearing masks. This will be assessed by a follow up survey question “In the last 14 days, how often did you wear a mask whenever you were in public spaces with other people? Heterogeneity Analysis. According to Africa CDC vaccine hesitancy survey of March 2021, those who are more skeptical towards COVID-19 vaccines tend to be female, young people, those who are unemployed and those living in cities and therefore, with respect to our treatments we expect female, young individuals, unemployed and those living in cities to react less to our treatments. Moreover, with respect to our EMPATHY and SELF-INTEREST treatments, we expect women to be more empathetic and have differential discount factors of time relative to men (Falk, et al., 2018). Similarly, because younger people have more time relative to older people, we expect their preferences for time but also others to differ. Finally, individuals who are unemployed and/or rural residents will have relative lower incomes than the employed/urban dwellers and we also know that incomes matter for risk preferences. Hence, we anticipate sex, age, employment status and urban residency will display heterogeneous effects. To capture this, we will run the analysis by regressing outcomes on an interaction between the treatment dummy and the characteristic. We also going to do a “change-from-baseline” analysis for no more than 4,766 respondents for the 6 outcomes we currently have some data on for each of the six (6) outcomes along with covariates included as well.

Cited by

No citation data available for this registration yet.

Keywords